Uncategorized

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company’s proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 Read More »

Imprimir antenas

En un avance sin precedentes, unos científicos han creado un nuevo compuesto que puede utilizarse para fabricar, mediante impresión 3D, antenas para telecomunicaciones y otros dispositivos similares.   La innovación es obra de un equipo internacional encabezado por Omid N …

Imprimir antenas Read More »

Scroll to Top